KRAS and neoplasm: Conversely, gene panels remain the predominant method for the detection of somatic driver mutations in tumor tissue, alongside WES in some institutions, given their high coverage of exonic regions where the majority of actionable alterations reside (e.g., EGFR, BRAF, PIK3CA, KRAS, BRCA1/2) [23,24].